Skip to main content
Erschienen in: Studies in Comparative International Development 2/2015

01.06.2015

Narrowing the Gaps in Global Disputes: the Case of Counterfeits in Kenya

verfasst von: Nitsan Chorev

Erschienen in: Studies in Comparative International Development | Ausgabe 2/2015

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

This article investigates the nature and potential trajectories of global disputes. Conventional accounts of global disputes often see them as inherently open-ended so that actors can always roll back previous defeats; alternatively, path-dependent accounts emphasize the likelihood of those who prevail in early struggles to reproduce their advantaged position. Like path-dependent accounts, I argue that disputes are nested, so that the goals and possible outcomes of new disputes are bounded by the results of earlier disputes—but rather than enlarging the gap between the parties to the dispute by reproducing advantages, nested disputes, on the contrary, lead to the narrowing of positions and to lower stakes. I illustrate this argument by describing two constitutive moments in the debate over intellectual property rights in Kenya: first, the debate around the Industrial Property Act over the exceptions to intellectual property rights; second, the debate around the Anti-Counterfeit Act over whether anti-counterfeit measures should apply to medicines.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Earlier versions of this paper were introduced in the “Access to Medicines in the Global South” workshop at Brown University; “The Future of Democracy After Neoliberalism: Social Movements in a Globalizing World” workshop at the University of Tokyo; and “Global Diffusion” workshop at Princeton University. I would like to thank all of the participants for their valuable comments, including Kenneth Shadlen, Peter Evans, Andreas Wimmer, and Takeshi Wada.
 
2
Compulsory licensing allows the government, without the consent of the patent holder, to grant a license to a third-party manufacturer to commercialize a patented invention; government use allows the government, without the consent of the patent holder, to make direct use of the patent; parallel importation allows for the purchase of a patented drug from a legitimate third party (Musungu and Oh 2006).
 
3
Products are falsely labeled if they provide wrong information on the label with regard to the content, date of manufacture, place of manufacture, or date of expiry; products are spurious drugs if contrary to the label they contain no active ingredient or a wrong active ingredient or an insufficient amount of active ingredient; substandard drugs are low-quality drugs caused by poor manufacturing practices, poor transportation techniques or poor storage facilities.
 
5
Differentiating between counterfeits and substandard drugs is essential because the legal means required to prevent substandard drugs from reaching the market are very different from the means recommended against counterfeits.
 
6
Interview by the author with Ahmed Mohamed (PPB), May 29, 2012.
 
7
Interview by the author with Beijing-Holley Cotec in Kenya, May 25, 2012; interview by the author with Omaera, May 22, 2012
 
8
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012.
 
9
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012.
 
10
Interview by the author with Wilberforce O. Wanyanga, Kenya, May 29, 2012.
 
11
Interview by the author with Peter Munyi (HAI), Kenya, June 21, 2012.
 
12
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012.
 
13
Interview by the author with Wilberforce O. Wanyanga, Kenya, May 29, 2012.
 
14
Ibid.
 
15
Ibid.
 
16
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012; interview by the author with Wilberforce O. Wanyanga, Kenya, May 29, 2012.
 
17
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012.
 
18
Interview by the author with Wilberforce O. Wanyanga, May 29, 2012, Siringi 2001a.
 
19
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012.
 
20
Ibid.
 
21
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012; interview by the author with David Njuguna (KIPI), Kenya, May 24, 2012.
 
22
Interview by the author with Rakesh Vinayak (Surgipharm), Kenya, May 21, 2012; interview by the author with Anastasia Nyalita (Bayer), Kenya, May 23, 2012.
 
23
Interview by the author with Kamamia Wa Murichu (KPDA), Kenya, June 5, 2012; interview by the author with Ravi Menon (Jubilant), Kenya, June 11, 2012.
 
24
Interview by the author with Rakesh Vinayak (Surgipharm), Kenya, May 21, 2012.
 
25
Interview by the author with Anastasia Nyalita (Bayer), Kenya, May 23, 2012.
 
27
Interview by the author with Gichinga Ndirangu (HAI), Kenya, June 7, 2012.
 
28
Ibid.
 
29
Interview by the author with Wariara Mugo (MSF), Kenya, May 23, 2012.
 
30
Message from Christa Cepuch and Peter Munyi (HAI) to [IP-Health] available at http://​lists.​essential.​org/​pipermail/​ip-health/​2009-January/​013355.​html
 
32
Ibid.
 
33
Ibid.
 
34
Ibid.
 
35
Interview by the author with William M. K. Mwatu (GSK), Kenya, May 28, 2012; Interview by the author with Ahmed Mohamed (PPB), May 29, 2012.
 
36
Interview by the author with William M. K. Mwatu (GSK), Kenya, May 28, 2012.
 
37
Interview by the author with Ahmed Mohamed (PPB), May 29, 2012.
 
38
Message from Christa Cepuch and Peter Munyi (HAI) to [IP-Health] available at http://​lists.​essential.​org/​pipermail/​ip-health/​2009-January/​013355.​html
 
39
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012.
 
40
Message from Christa Cepuch and Peter Munyi (HAI) to [IP-Health] available at http://​lists.​essential.​org/​pipermail/​ip-health/​2009-January/​013355.​html; MSF 2010.
 
41
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012; interview by the author with Wilberforce O. Wanyanga, Kenya, May 29, 2012.
 
42
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012.
 
43
Interview by the author with Moses Mwangi (KAPI), Kenya, May 18, 2012; interview by the author with William M. K. Mwatu (GSK), Kenya, May 28, 2012.
 
44
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012.
 
45
Ibid.
 
46
Ibid.
 
47
Interview by the author with Moses Mwangi (KAPI), Kenya, May 18, 2012.
 
48
Interview by the author with Peter Munyi (HAI), Kenya, June 21, 2012.
 
49
Interview by the author with Peter Hime (Kaplan & Stratton law firm), Kenya, June 18, 2012.
 
51
Ibid.
 
52
Interview by the author with Christa Cepuch (HAI & MSF), Kenya, May 24, 2012.
 
53
Interview by the author with Peter Hime (Kaplan & Stratton law firm), Kenya, June 18, 2012.
 
54
However, we should be mindful of the fact that while multinational pharmaceutical companies were heavily involved in lobbying for TRIPS (Sell 2003), health activists’ mobilization against TRIPS started in earnest only with the development of effective anti-AIDS medications, after TRIPS had already been signed.
 
55
Of course, there are ways by which parties can capture but then distort otherwise laudable goals. One could argue therefore that the warnings against counterfeit drugs—just like the warnings against generic drugs earlier on—were nothing but a façade. Still, pretending to be concerned with safety does have the outcome, even if unintended, of improving quality standards of drugs.
 
56
The petitioners “submitted that Article 51 of [TRIPS] limits the use of the term ‘counterfeiting’ to counterfeit trademark goods; that the TRIPS Agreement forms part of Kenyan law in line with the provisions of Article 2 of the Constitution of Kenya; that the term ‘counterfeit’ as used in the Act goes beyond its internationally accepted legal meaning.”
 
Literatur
Zurück zum Zitat Abbott A. Sequences of social events: concepts and methods for the analysis of order in social processes. Hist Methods. 1983;16(4):129–47.CrossRef Abbott A. Sequences of social events: concepts and methods for the analysis of order in social processes. Hist Methods. 1983;16(4):129–47.CrossRef
Zurück zum Zitat Abbott FM, Reichman JH. The Doha round’s public health legacy: strategies for the production and diffusion of patented medicines under the Amended Trips Provisions. J Int Econ Law. 2007;10(4):921–87.CrossRef Abbott FM, Reichman JH. The Doha round’s public health legacy: strategies for the production and diffusion of patented medicines under the Amended Trips Provisions. J Int Econ Law. 2007;10(4):921–87.CrossRef
Zurück zum Zitat Amin AA, Kowaro GO. Antimalaria Drug Quality in Africa. J Cli Pharm Ther. 2007;32:429–440. Amin AA, Kowaro GO. Antimalaria Drug Quality in Africa. J Cli Pharm Ther. 2007;32:429–440.
Zurück zum Zitat Amin AA, Snow RW, Kokwaro GO. The quality of sulfadoxine-pyrimethamine and amodiaquine in the Kenyan retail sector. J Clin Pharm Ther. 2005;30:559–65.CrossRef Amin AA, Snow RW, Kokwaro GO. The quality of sulfadoxine-pyrimethamine and amodiaquine in the Kenyan retail sector. J Clin Pharm Ther. 2005;30:559–65.CrossRef
Zurück zum Zitat Amon JJ. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Glob Health. 2008;4:5.CrossRef Amon JJ. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Glob Health. 2008;4:5.CrossRef
Zurück zum Zitat Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health. 2007;12:68–74. Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health. 2007;12:68–74.
Zurück zum Zitat Attaran A, Bate R. Deadly Fake Medicines. 2012. New York Times, November 20. Attaran A, Bate R. Deadly Fake Medicines. 2012. New York Times, November 20.
Zurück zum Zitat Bate R. Making a killing: the deadly implications of the counterfeit drug trade. Washington, D.C.: The AEI Press; 2008. Bate R. Making a killing: the deadly implications of the counterfeit drug trade. Washington, D.C.: The AEI Press; 2008.
Zurück zum Zitat Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa—a six country study. PLoS ONE. 2008;3, e2132.CrossRef Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa—a six country study. PLoS ONE. 2008;3, e2132.CrossRef
Zurück zum Zitat Baumgartner FR, Jones BD. Agendas and instability in American politics. Chicago: University of Chicago Press; 1993. Baumgartner FR, Jones BD. Agendas and instability in American politics. Chicago: University of Chicago Press; 1993.
Zurück zum Zitat Cerny P. From ‘iron triangles’ to ‘golden pentangles’? Globalizing the policy process. Glob Gov. 2001;7(4):397–410. Cerny P. From ‘iron triangles’ to ‘golden pentangles’? Globalizing the policy process. Glob Gov. 2001;7(4):397–410.
Zurück zum Zitat Chepkwony HK, Mwaura N, Guantai E, Gathoni E, Kamau FN, Mbae E, et al. Quality of antimalarial drugs analysed in the National Quality Control Laboratory during the period 2002–2005. East Cent Afr J Pharm Sci. 2007;10:59–62. Chepkwony HK, Mwaura N, Guantai E, Gathoni E, Kamau FN, Mbae E, et al. Quality of antimalarial drugs analysed in the National Quality Control Laboratory during the period 2002–2005. East Cent Afr J Pharm Sci. 2007;10:59–62.
Zurück zum Zitat Chorev N. Political and institutional maneuvers in international trade negotiations: the United States and the Doha development round. In: Blaas W, Becker J, editors. Strategic arena switching in international trade negotiations. Aldershot: Ashgate; 2006. Chorev N. Political and institutional maneuvers in international trade negotiations: the United States and the Doha development round. In: Blaas W, Becker J, editors. Strategic arena switching in international trade negotiations. Aldershot: Ashgate; 2006.
Zurück zum Zitat Chorev N. Changing global norms through reactive diffusion: the case of intellectual property protection of AIDS drugs. Am Sociol Rev. 2012a;77(5):1–23. Chorev N. Changing global norms through reactive diffusion: the case of intellectual property protection of AIDS drugs. Am Sociol Rev. 2012a;77(5):1–23.
Zurück zum Zitat Chorev N. The World Health Organization between north and south. Ithaca: Cornell University Press; 2012b. Chorev N. The World Health Organization between north and south. Ithaca: Cornell University Press; 2012b.
Zurück zum Zitat Cockburn P, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2, e100.CrossRef Cockburn P, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2, e100.CrossRef
Zurück zum Zitat Correa C. Implications of bilateral free trade agreements on access to medicines. Bull World Health Organ. 2006;401. Correa C. Implications of bilateral free trade agreements on access to medicines. Bull World Health Organ. 2006;401.
Zurück zum Zitat Deere C. The implementation game: the TRIPS agreement and the global politics of intellectual property reform in developing countries. London: Oxford University Press; 2008.CrossRef Deere C. The implementation game: the TRIPS agreement and the global politics of intellectual property reform in developing countries. London: Oxford University Press; 2008.CrossRef
Zurück zum Zitat Drahos P. Four lessons for developing countries from the trade negotiations over access to medicines. Liverpool Law Rev. 2007;28:11.CrossRef Drahos P. Four lessons for developing countries from the trade negotiations over access to medicines. Liverpool Law Rev. 2007;28:11.CrossRef
Zurück zum Zitat Drahos P. The global governance of knowledge: patent offices and their clients. Cambridge: Cambridge University Press; 2010.CrossRef Drahos P. The global governance of knowledge: patent offices and their clients. Cambridge: Cambridge University Press; 2010.CrossRef
Zurück zum Zitat Editorial. The Problem of Fake and Useless Drugs. 2012. New York Times, November 21. Editorial. The Problem of Fake and Useless Drugs. 2012. New York Times, November 21.
Zurück zum Zitat Helfer LR. Regime shifting: the TRIPS agreement and new dynamics of international intellectual property lawmaking. Yale J Int Law. 2004;29(1):1–83. Helfer LR. Regime shifting: the TRIPS agreement and new dynamics of international intellectual property lawmaking. Yale J Int Law. 2004;29(1):1–83.
Zurück zum Zitat Kapstein EB, Busby JW. AIDS drugs for all: social movements and market transformations. Cambridge: Cambridge University Press; 2013.CrossRef Kapstein EB, Busby JW. AIDS drugs for all: social movements and market transformations. Cambridge: Cambridge University Press; 2013.CrossRef
Zurück zum Zitat Keck ME, Sikkink K. Activists beyond borders: advocacy networks in international politics. Ithaca: Cornell University Press; 1998. Keck ME, Sikkink K. Activists beyond borders: advocacy networks in international politics. Ithaca: Cornell University Press; 1998.
Zurück zum Zitat Kibwage IO, Ngugi JK. Sulphadoxine⁄pyrimethamine tablet products on the Kenyan market: quality concerns. East Cent Afr J Pharm Sci. 2000;3:14–9. Kibwage IO, Ngugi JK. Sulphadoxine⁄pyrimethamine tablet products on the Kenyan market: quality concerns. East Cent Afr J Pharm Sci. 2000;3:14–9.
Zurück zum Zitat Kimani D. Illegally Imported, Fake Drugs Flood Kenya. 2004. The East African. 10 May. Kimani D. Illegally Imported, Fake Drugs Flood Kenya. 2004. The East African. 10 May.
Zurück zum Zitat Kimani D. Anti-Fakes Bill Threatens Access to Generics. 2008. The East African. 6 September. Kimani D. Anti-Fakes Bill Threatens Access to Generics. 2008. The East African. 6 September.
Zurück zum Zitat Lewis-Lettington R, Munyi P. Willingness and Ability to Use TRIPs Flexibilities: Kenya Case Study. DFID; 2004. Lewis-Lettington R, Munyi P. Willingness and Ability to Use TRIPs Flexibilities: Kenya Case Study. DFID; 2004.
Zurück zum Zitat Mahoney J. Path dependence in historical sociology. Theory Soc. 2000;29:507–48.CrossRef Mahoney J. Path dependence in historical sociology. Theory Soc. 2000;29:507–48.CrossRef
Zurück zum Zitat Mey BP. Unfettered consumer access to affordable therapies in the post-TRIPS era: a dead-end journey for patients? Kenya and India case studies. J World Intellect Prop. 2010;13(3):403–73.CrossRef Mey BP. Unfettered consumer access to affordable therapies in the post-TRIPS era: a dead-end journey for patients? Kenya and India case studies. J World Intellect Prop. 2010;13(3):403–73.CrossRef
Zurück zum Zitat Ministry of Health, WHO and Health Action International. Antimalarial medicines in Kenya: Availability, quality and registration status, December 2007. Ministry of Health, WHO and Health Action International. Antimalarial medicines in Kenya: Availability, quality and registration status, December 2007.
Zurück zum Zitat Ministry of Medical Services and the Ministry of Public Health. Reforming the Pharmaceutical Sector to Ensure Equitable Access to Essential Medicines and Essential Health Technologies for all Kenyans. Sessional Paper on National Pharmaceutical Policy. Nairobi: Kenya; 2010. Ministry of Medical Services and the Ministry of Public Health. Reforming the Pharmaceutical Sector to Ensure Equitable Access to Essential Medicines and Essential Health Technologies for all Kenyans. Sessional Paper on National Pharmaceutical Policy. Nairobi: Kenya; 2010.
Zurück zum Zitat MSF. Fatal Confusion: How Kenya’s 2008 Anti-Counterfeit Bill Endangers Access to Medicines. A Médecins Sans Frontières Briefing Document; 2008. MSF. Fatal Confusion: How Kenya’s 2008 Anti-Counterfeit Bill Endangers Access to Medicines. A Médecins Sans Frontières Briefing Document; 2008.
Zurück zum Zitat MSF. Fatal Flaws: How Kenya’s 2008 Anti-Counterfeit Act Could Endanger Access to Medicines. A Médecins Sans Frontières briefing document; 2010. MSF. Fatal Flaws: How Kenya’s 2008 Anti-Counterfeit Act Could Endanger Access to Medicines. A Médecins Sans Frontières briefing document; 2010.
Zurück zum Zitat Musungu S, Oh C. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? Geneva: South Centre and the World Health Organization; 2006. Musungu S, Oh C. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? Geneva: South Centre and the World Health Organization; 2006.
Zurück zum Zitat Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in Southeast Asia and sub-Saharan Africa. Lancet. 2012;12:488–96.CrossRef Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in Southeast Asia and sub-Saharan Africa. Lancet. 2012;12:488–96.CrossRef
Zurück zum Zitat Neondo H. Kenyan High Court set to make landmark decision on access to generic medicines. African Science New; 2012. Neondo H. Kenyan High Court set to make landmark decision on access to generic medicines. African Science New; 2012.
Zurück zum Zitat Newton PN, et al. Poor Quality Vital Anti-Malarials in Africa - An Urgent Neglected Public Health Priority. Malaria Journal. 2011;10:352. Newton PN, et al. Poor Quality Vital Anti-Malarials in Africa - An Urgent Neglected Public Health Priority. Malaria Journal. 2011;10:352.
Zurück zum Zitat O’Brien R, Goetz AM, Scholte JA, Williams M, editors. Contesting global governance: multilateral economic institutions and global social movements. Cambridge: Cambridge University Press; 2000. O’Brien R, Goetz AM, Scholte JA, Williams M, editors. Contesting global governance: multilateral economic institutions and global social movements. Cambridge: Cambridge University Press; 2000.
Zurück zum Zitat Orwa JA, Keter K, Ouko PA, Kibwage O, Rukunga M. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya. East Afr Med J. 2004;81(6):287–92.CrossRef Orwa JA, Keter K, Ouko PA, Kibwage O, Rukunga M. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya. East Afr Med J. 2004;81(6):287–92.CrossRef
Zurück zum Zitat Outterson K, Smith R. Counterfeit drugs: the good, the bad and the ugly. Albany Law J Sci Technol. 2006;16:525–43. Outterson K, Smith R. Counterfeit drugs: the good, the bad and the ugly. Albany Law J Sci Technol. 2006;16:525–43.
Zurück zum Zitat Pharma Focus Asia. Counterfeit Drugs: The Issue of Key Concern and its impact on Indian Pharma Industry; 2009. Pharma Focus Asia. Counterfeit Drugs: The Issue of Key Concern and its impact on Indian Pharma Industry; 2009.
Zurück zum Zitat Pierson P. Increasing returns, path dependence, and the study of politics. Am Polit Sci Rev. 2000;94:251–68.CrossRef Pierson P. Increasing returns, path dependence, and the study of politics. Am Polit Sci Rev. 2000;94:251–68.CrossRef
Zurück zum Zitat Rosenau JN. Governing the ungovernable: the challenge of a global disaggregation of authority. Regul Gov. 2007;1:88–97.CrossRef Rosenau JN. Governing the ungovernable: the challenge of a global disaggregation of authority. Regul Gov. 2007;1:88–97.CrossRef
Zurück zum Zitat Rosenau JN, Czempiel E-O, editors. Governance without government: order and change in world politics. Cambridge: Cambridge University Press; 1992. Rosenau JN, Czempiel E-O, editors. Governance without government: order and change in world politics. Cambridge: Cambridge University Press; 1992.
Zurück zum Zitat Schneiberg M, Bartley T. Organizations, regulation, and economic behavior: regulatory dynamics and forms from the nineteenth to twenty-first century. Annu Rev Law Soc Sci. 2008;4:31–61.CrossRef Schneiberg M, Bartley T. Organizations, regulation, and economic behavior: regulatory dynamics and forms from the nineteenth to twenty-first century. Annu Rev Law Soc Sci. 2008;4:31–61.CrossRef
Zurück zum Zitat Sell S. Private power, public law: the globalization of intellectual property rights. Cambridge: Cambridge University Press; 2003.CrossRef Sell S. Private power, public law: the globalization of intellectual property rights. Cambridge: Cambridge University Press; 2003.CrossRef
Zurück zum Zitat Sell S. TRIPS was never enough: vertical forum shifting, FTAs, ACTA, and TPP. J Intellect Prop Law. 2011;18:447–78. Sell S. TRIPS was never enough: vertical forum shifting, FTAs, ACTA, and TPP. J Intellect Prop Law. 2011;18:447–78.
Zurück zum Zitat Sell S. The Global IP Upward Ratchet, Anti-Counterfeiting and Piracy Enforcement Efforts: The State of Play. 2010. PIJIP Research Paper no. 15. Washington, DC: American University Washington College of Law Sell S. The Global IP Upward Ratchet, Anti-Counterfeiting and Piracy Enforcement Efforts: The State of Play. 2010. PIJIP Research Paper no. 15. Washington, DC: American University Washington College of Law
Zurück zum Zitat Sell SK, Prakash A. Using ideas strategically: the contest between business and NGO networks in intellectual property rights. Int Stud Q. 2004;48:143–75.CrossRef Sell SK, Prakash A. Using ideas strategically: the contest between business and NGO networks in intellectual property rights. Int Stud Q. 2004;48:143–75.CrossRef
Zurück zum Zitat Sewell Jr WH. Three temporalities: towards an eventful sociology. In: McDonald TJ, editor. The historic turn in the human sciences. Ann Arbor: University of Michigan Press; 1996. Sewell Jr WH. Three temporalities: towards an eventful sociology. In: McDonald TJ, editor. The historic turn in the human sciences. Ann Arbor: University of Michigan Press; 1996.
Zurück zum Zitat Shadlen KC. Patents and pills, power and procedure: the north–south politics of public health in the WTO. Stud Comp Int Dev. 2004;39(3):76–108.CrossRef Shadlen KC. Patents and pills, power and procedure: the north–south politics of public health in the WTO. Stud Comp Int Dev. 2004;39(3):76–108.CrossRef
Zurück zum Zitat Shadlen KC. The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. Comp Polit. 2009;42(1):41–58.CrossRef Shadlen KC. The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. Comp Polit. 2009;42(1):41–58.CrossRef
Zurück zum Zitat Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2(9):839–45.CrossRef Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2(9):839–45.CrossRef
Zurück zum Zitat Siringi S. Generic drugs battle moves from South Africa to Kenya. Lancet. 2001a;357:1600.CrossRef Siringi S. Generic drugs battle moves from South Africa to Kenya. Lancet. 2001a;357:1600.CrossRef
Zurück zum Zitat Siringi S. Kenya allows parallel importation of drugs. Lancet. 2001b;357:2034. Siringi S. Kenya allows parallel importation of drugs. Lancet. 2001b;357:2034.
Zurück zum Zitat Thambisetty S. Timing, continuity, and change in the patent system. In: Haunss S, Shadlen KC, editors. The politics of intellectual property. Northhampton: Edward Elgar; 2009. Thambisetty S. Timing, continuity, and change in the patent system. In: Haunss S, Shadlen KC, editors. The politics of intellectual property. Northhampton: Edward Elgar; 2009.
Zurück zum Zitat Thoithi GN, Abuga KO, Nguyo JM, Mukindia G, Kingondu O, Ngugi JK, et al. Drug quality control work in drug analysis and research unit: observation during 1996–2000. East Cent Afr J Pharm Sci. 2002;5(1):28–32. Thoithi GN, Abuga KO, Nguyo JM, Mukindia G, Kingondu O, Ngugi JK, et al. Drug quality control work in drug analysis and research unit: observation during 1996–2000. East Cent Afr J Pharm Sci. 2002;5(1):28–32.
Zurück zum Zitat Thoithi G, Abuga K, Nguyo J, et al. Drug quality control in Kenya: observation in the drug analysis and research unit during the period 2001–2005. East Cent Afr J Pharm Sci. 2008;11:74–81. Thoithi G, Abuga K, Nguyo J, et al. Drug quality control in Kenya: observation in the drug analysis and research unit during the period 2001–2005. East Cent Afr J Pharm Sci. 2008;11:74–81.
Zurück zum Zitat Unnikrishnan CH. Indian Drug Makers Worried by East Africa’s Legal Proposals. 2010. LiveMint, Feb 16. Unnikrishnan CH. Indian Drug Makers Worried by East Africa’s Legal Proposals. 2010. LiveMint, Feb 16.
Zurück zum Zitat World Health Organization. Counterfeit drugs—Report of a WHO/IFPMA Workshop, 1992. WHO/DMP/CFD/92. Geneva: World Health Organization; 1992. World Health Organization. Counterfeit drugs—Report of a WHO/IFPMA Workshop, 1992. WHO/DMP/CFD/92. Geneva: World Health Organization; 1992.
Zurück zum Zitat World Health Organization. The dangers of counterfeit and substandard active pharmaceutical ingredients. WHO Drug Inf. 1997;11(3):123–7. World Health Organization. The dangers of counterfeit and substandard active pharmaceutical ingredients. WHO Drug Inf. 1997;11(3):123–7.
Zurück zum Zitat World Health Organization. Report of the International Workshop on Counterfeit Drugs. WHO/DRS/CFD/98.1. Geneva: World Health Organization; 1998. World Health Organization. Report of the International Workshop on Counterfeit Drugs. WHO/DRS/CFD/98.1. Geneva: World Health Organization; 1998.
Zurück zum Zitat World Health Organization. The quality of antimalarials. A study in selected African countries. Geneva: World Health Organization; 2003. World Health Organization. The quality of antimalarials. A study in selected African countries. Geneva: World Health Organization; 2003.
Zurück zum Zitat World Health Organization. Survey of the quality of antiretroviral medicines circulating in selected African countries. Geneva: World Health Organization; 2007. World Health Organization. Survey of the quality of antiretroviral medicines circulating in selected African countries. Geneva: World Health Organization; 2007.
Zurück zum Zitat World Health Organization. Experience with Supporting Pharmaceutical Policies and Systems in Kenya: Progress, Lessons and the Role of WHO. WHO/EMP/MPC/2010.2.; 2010a. World Health Organization. Experience with Supporting Pharmaceutical Policies and Systems in Kenya: Progress, Lessons and the Role of WHO. WHO/EMP/MPC/2010.2.; 2010a.
Zurück zum Zitat World Health Organization. Preliminary Unedited Draft. Preliminary Draft Survey on National Legislation on Counterfeit Medicines. Working document WHO/ACM/1.; 2010b. World Health Organization. Preliminary Unedited Draft. Preliminary Draft Survey on National Legislation on Counterfeit Medicines. Working document WHO/ACM/1.; 2010b.
Zurück zum Zitat World Health Organization. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa; 2011. World Health Organization. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa; 2011.
Metadaten
Titel
Narrowing the Gaps in Global Disputes: the Case of Counterfeits in Kenya
verfasst von
Nitsan Chorev
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Studies in Comparative International Development / Ausgabe 2/2015
Print ISSN: 0039-3606
Elektronische ISSN: 1936-6167
DOI
https://doi.org/10.1007/s12116-015-9183-5

Weitere Artikel der Ausgabe 2/2015

Studies in Comparative International Development 2/2015 Zur Ausgabe